RxDoctor Payments Data

Steven Creps, MD

Family Medicine · Shermans Dale, PANPI 1669482527

Payments from drug & device makers

$4,802in general payments, 2019–2025

Across 320 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$4K
  • Lilly USA, LLC$314
  • Pfizer$202
  • Sanofi-aventis U.S. LLC$98
  • Merck$65
  • E.r. Squibb & Sons, L.L.C.$59
  • plus $193 from 10 others

What the payments were for

  • Food & beverage$4,802100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,802 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$122,245
Medicare patients
475
Services billed
1,948

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$139,425
EliquisApixaban407$139,376
JardianceEmpagliflozin143$95,507
TrulicityDulaglutide48$41,974
XifaxanRifaximin29$37,832
RybelsusSemaglutide14$27,192
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$26,345
XareltoRivaroxaban57$25,936
OxycontinOxycodone Hcl14$22,668
JanuviaSitagliptin Phosphate26$19,488
MounjaroTirzepatide17$19,126
Xtampza ErOxycodone Myristate12$13,364
Tresiba Flextouch U-200Insulin Degludec24$12,214
Atorvastatin Calcium1,280$12,036
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$11,926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$3,871$166,617115 claims
PfizerEliquis$202$139,376407 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta$22$111,316196 claims
Lilly USA, LLCTrulicity, Mounjaro$314$61,10065 claims
GSKTrelegy Ellipta, Anoro Ellipta$28$38,27148 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$19$37,83229 claims
MerckJanuvia, Dulera, Janumet$65$27,97064 claims
Johnson & JohnsonXarelto$49$25,93657 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Shermans Dale

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →